"Retina Group of Washington-Chevy Chase, Maryland is an eye care center & ophthalmology clinic with retina specialists & vitreoretinal surgeon ophthalmologists providing eye exams, diagnosis & treatment for retina diseases & problems including retinal detachment & tears, macular degeneration (AMD), diabetic retinopathy, retinal vascular disease such as retinal vein & artery occlusion, retinal membranes & macular hole. Our retina specialists perform retina injections for AMD & diabetic eye problems, and laser photocoagulation treatment in our offices as well as performing retina surgery such as scleral buckle, vitrectomy & retinopexy. Our retinal physicians conduct clinical trials & a fellowship program for vitreoretinal disease."

During the past decade, Retina Group of Washington conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 12 clinical trials were completed, i.e. on average, 48% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 10 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Group of Washington" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Genentech, Inc." with 3 trials sponsored, "Kodiak Sciences Inc" with 3 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored and "Clearside Biomedical, Inc." with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Group of Washington" #1 collaborator was "National Eye Institute (NEI)" with 2 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Milton S. Hershey Medical Center" with 1 trials as a collaborator, "National Center for Complementary and Integrative Health (NCCIH)" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Retina Group of Washington" are "Geographic Atrophy" (5 trials), "Diabetic Macular Edema" (4 trials), "Macular Degeneration" (4 trials), "Macular Edema" (3 trials) and "Retinal Vein Occlusion" (3 trials). Many other conditions were trialed in "Retina Group of Washington" in a lesser frequency.

Most popular intervention types in "Retina Group of Washington" are "Drug" (29 trials), "Other" (7 trials), "Device" (3 trials), "Procedure" (3 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (11 trials), "Aflibercept" (6 trials), "Faricimab" (6 trials), "KSI-301" (3 trials) and "Intravitreal Ranibizumab 0.5 mg Injection" (2 trials). Other intervention names were less common.

The vast majority of trials in "Retina Group of Washington" are 32 trials for "All" genders.

Currently, there are NaN active trials in "Retina Group of Washington". undefined are not yet recruiting, 2 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Retina Group of Washington, 1 suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Group of Washington, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".